<DOC>
	<DOCNO>NCT01384747</DOCNO>
	<brief_summary>- Fimasartan beneficial stabilizing plaque vulnerability compare control group defer coronary lesion . - Fimasartan beneficial reduce total plaque volume compare control group defer coronary lesion . - Fimasartan beneficial reduce functional impairment stenotic lesion ( assessed FFR : Fractional Flow Reserve ) defer coronary lesion .</brief_summary>
	<brief_title>Effect Fimasartan Modification Atheroma Vulnerability DEFERred Coronary Disease ( FIMA-DEFER )</brief_title>
	<detailed_description>Prospective , double-blind , randomized clinical study enrollment patient least 18 year age require coronary angiography clinical indication hypertension define systolic blood pressure &gt; 140mmHg diastolic blood pressure &gt; 90mmHg . Inclusion require least one deferred coronary lesion 1 ) visually-estimated angiographic % diameter stenosis 20-50 % 2 ) % diameter stenosis &gt; 50 % without evidence inducible ischemia . The target vessel IVUS interrogation must undergo angioplasty ( deferred lesion ) 50 % luminal narrowing throughout target segment . Patients meet inclusion criterion without exclusion criterion randomize 1:1 ( Fimasartan 60-120 mg v placebo ) . All subject follow 1 year serial VH-IVUS conventional IVUS evaluation . Also , OCT sub-study perform select patient lesion least 20 mm distally locate coronary ostium . All patient blindly assign control Fimasartan daily 1:1 ratio prescribe 1year .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Plaque , Atherosclerotic</mesh_term>
	<criteria>1 . Hypertensive patient ( systolic blood pressure &gt; 140mmHg diastolic blood pressure &gt; 90mmHg ) medically treat hypertension normal blood pressure undergo coronary angiography clinical indication 2 . 18 &lt; Age &lt; 85 3 . Patient receive informed consent 4. least one deferred coronary lesion 1 ) visuallyestimated angiographic % diameter stenosis 2050 % 2 ) % diameter stenosis &gt; 50 % without evidence inducible ischemia ( FFR â‰¥ 0.8 negative perfusion defect thallium scan negative treadmill test ) 1 . Planned cardiac surgery ( e.g. , CABG , valve repair replacement , aneurysmectomy ) plan major noncardiac surgery within study period 2 . Planned performance PCI CABG target vessel branch contain index 3 . Evidence congestive heart failure , leave ventricular ejection fraction &lt; 40 % 4 . Stroke resuscitate sudden death past 6 month 5 . Chronic disease require treatment oral , intravenous , intraarticular corticosteroid ( use topical , inhaled , nasal corticosteroid permissible ) 6 . A diagnosis cancer ( superficial squamous basal cell skin cancer ) past 3 year current treatment active cancer 7 . Any clinically significant abnormality identify screen visit , physical examination , laboratory test , electrocardiogram , judgment Investigator , would preclude safe completion study 8 . Significant renal disease manifest serum creatinine &gt; 1.5 mg/dL 9 . Hepatic disease biliary tract obstruction , significant hepatic enzyme elevation ( ALT AST &gt; 3 time upper limit normal ) 10 . Active hepatitis B C carrier 11 . Hypotension ( systolic blood pressure &lt; 90 mmHg ) 12 . Patients already take ACE inhibitor ARBs 13 . Patients STEMI require primary PCI 14 . Patients pregnant breastfeed childbearing potential 15 . Patients lack intention effective contraception 16 . Patients history previous enrollment clinical trial within 3 month 17 . Allergic contraindicate Angiotensin II antagonists 18 . History arterial bypass angioplastic intervention involve target vessel 19 . Luminal narrowing leave main &gt; 50 % visual inspection angiogram 20 . Visuallyestimated angiographic reference segment diameter &lt; 2.75mm &gt; 4.0 mm 21 . Presence thrombus complex plaque morphology target vessel suggest high likelihood distal embolism 22 . Severe tortuosity target vessel anatomical reason investigator deem 23 . Inappropriate IVUS procedure . Vessel thrombus ( GSIVUS ) , moderate severe calcification , angulation 24 . Culprit vessel AMI 25 . RWMA ( Regional Wall Motion Abnormality ) scar tissue territory subtend studied lesion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>